- Home
- HTGC vs DNLI Comparison
HTGC vs DNLI Comparison
Compare HTGC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTGC | DNLI |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | HTGC | DNLI |
|---|---|---|
| Price | $13.75 | $18.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $18.67 | ★ $34.09 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 13.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.28 | N/A |
| Revenue Next Year | $4.83 | $188.54 |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.77 | $10.57 |
| 52 Week High | $19.67 | $23.77 |
Technical Indicators
Market Signals| Indicator | HTGC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 31.89 | 39.40 |
| Support Level | N/A | $13.52 |
| Resistance Level | $14.69 | $20.12 |
| Average True Range (ATR) | 0.37 | 1.20 |
| MACD | 0.05 | -0.19 |
| Stochastic Oscillator | 4.99 | 2.24 |
Price Performance
Historical ComparisonAbout HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.